Navigation Links
Kiadis Pharma to Receive GMP Manufacturing License and GMP Certificate
Date:7/22/2013

AMSTERDAM, July 23, 2013 /PRNewswire/ --

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that its Quality Control (QC) laboratory and the associated Quality system has been inspected for good-manufacturing-practice (GMP) by the Dutch Health Care Inspectorate (IGZ) and has fully met the EU GMP standards. As a result, Kiadis Pharma will receive a GMP manufacturing license and GMP certificate for its QC laboratory from the Dutch Ministry of Health, Welfare and Sport.  

GMP licensing and certification enables Kiadis Pharma to perform QC release-assays for the clinical trial manufacturing of the Company's lead product ATIR™, a cellular therapeutic that will enable partially mismatched donor stem cell transplants from family members in blood cancer patients.

Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma, commented: "This is an important milestone for Kiadis Pharma as we are committed to the highest standards of manufacturing. We are delighted that our QC laboratory and the associated Quality system will receive a GMP manufacturing license and GMP certificate. This not only attests to the quality that we have established at Kiadis Pharma, but secures the pathway to take ATIR™ to the next stage of development. ATIR™ is currently in an ongoing Phase II study to confirm and extend some exciting data. We expect the Phase II results in H1 2014."

About ATIR™

ATIR™ is a cell based medicinal product enabling stem cell transplantations using partially mismatched (haploidentical) family members as donors for patients suffering from blood cancer who lack a suitable standard of care matched donor. Stem cell transplantation is the only potentially curative treatment for many patients but a matching donor is available for only half of the p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
2. State Exchanges And Other Post-ACA Implementation Hinder 2014 Planning For Pharma
3. CRO Solutions, Inc. Announces Opening of New Division - VxP Pharma Services, Inc.
4. ResearchMoz.us: Biotechnology Market By Application (Biopharmacy, Bioservices, Bioagri, Bioindustrial), By Technology (Fermentation, Tissue Regeneration, PCR, Nanobiotechnology, DNA Sequencing & Others) - Global Industry Analysis, Size, Share, Growt
5. Imprimis Pharmaceuticals, Inc. Receives Institutional Review Board (IRB) Approval for its Phase III Clinical Trial Protocol; Phase III Clinical Trial to Begin in 3Q 2013
6. ANI Pharmaceuticals, Inc. Announces Date for Second Quarter 2013 Earnings Release
7. QRxPharma Announces Collaboration With Aesica
8. Aquavit Pharmaceuticals and U-Bio Med Enter Exclusive Worldwide License Agreement for Microneedle Technology (AQT-001)
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University
11. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014  Nektar Therapeutics (Nasdaq: ... the third quarter ended September 30, 2014 on Thursday, ... markets. Howard Robin , president and chief executive ... results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. ... and a live audio-only Webcast of the conference call ...
(Date:10/30/2014)... --  Auxilium Pharmaceuticals , Inc. (NASDAQ: ... today announced financial results for the third quarter ... corporate, commercial, regulatory and clinical development updates from ... pleased with the continued momentum and strong performance ... this quarter, especially the XIAFLEX franchise, which more ...
(Date:10/30/2014)...  TWi Pharmaceuticals, Inc. today announced that it has ... Drug Administration (FDA) on its Abbreviated New Drug Application ... generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® 23mg ... TWi Pharmaceuticals is preparing to launch the product in ... USA , at the earliest time ...
Breaking Medicine Technology:Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22
... EntreMed, Inc. (Nasdaq: ENMD ) announced today that ... with YA Global Master SPV Ltd. ("YA Global"), a fund ... has the option, at its sole discretion, to sell, from ... to YA Global.  Concurrent with the signing of the SEDA, ...
... NEWPORT NEWS, Va., June 28, 2011  Burlington Medical ... new product into its inventory. The Single Swing-Arm Drape ... protects the worker from any scattered beams of radiation ... The black vinyl drape is 39-and-a-half inches wide ...
Cached Medicine Technology:EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown 2EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown 3EntreMed Enters into $7.5 Million Equity Facility and Initiates $1.1 Million Drawdown 4Burlington Medical Supplies Introduces Single Swing-Arm Drape 2
(Date:10/30/2014)... PreDiabetes Centers , the pioneer in ... with a supply of sugardown®, a chewable dietary supplement ... sugar spikes. Learning how to control blood sugar levels ... a diabetes prevention plan. , Shoppers who spend $50 ... of sugardown. The offer expires November 30. , ...
(Date:10/30/2014)... By Tara Haelle ... (HealthDay News) -- More than 100 genes have been ... new studies report. And researchers say they are ... overall that may contribute to the disorder. Autism ... by communication and social difficulties and repetitive behaviors. An ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Horse ... therapeutic horseback riding to special needs individuals in the ... on Saturday, November 15 from 10-2:00 p.m. at Bailey's ... is open to the public and is designed to ... , Admission to the HSS Round-Up is free. Ticket ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... comes to heart disease, a new study finds women are ... symptoms that spell trouble. "The main danger is that ... or advanced stage of heart disease, there are simply fewer ... and research fellow at the Harvard School of Public Health, ... Foundation of Canada. In the study, researchers talked to ...
Breaking Medicine News(10 mins):Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Horse Sense & Sensitivity, Jacksonville Non-profit, To Hold 2nd Annual Round-Up 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Women Often Ignore Signs of Heart Trouble 2
... past have argued about the implications of Hormone Replacement Therapy ... A new study, however, has gone further to show that ... developing breast cancer// if they consumed alcoholic beverages. ,The ... pattern and on whether they were on HRT currently or ...
... have found that people who take anti-depressants to relieve ... developing gastrointestinal bleeding. The study which was conducted over ... were compared for hospitalizations due to upper GI bleeding ... on selective serotonin reuptake inhibitors, or SSRIs, were 3.6-times ...
... by a Diabetes Research Centre in India has shown that ... had considerable improvement when they followed safe practices advised by ... doctors discovering that many patients came to the Centre with ... their lives. They decided that a little change in lifestyle ...
... called 'HERS' conducted by researchers of the University of California, ... that Hormone Replacement Therapy (HRT) may be able to reduce ... develop diabetes as well. ,The study involved some women ... had "impaired fasting glucose" - a condition with some ...
... 61 previous studies of blood pressure and cardiovascular disease, which ... regardless of age and even if readings are in the ... reducing risk of strokes and heart attacks. ,The study ... that out of the 120,000 who died, 56,000 suffered fatal ...
... Chairman and Managing Director of Eli Lilly and Co., India, ... cut in the company's human insulin product 'Huminsulin', that its ... market by the end of this year. He added that ... use of human insulin products and the phasing out of ...
Cached Medicine News:Health News:Women on HRT should avoid alcohol 2
... Ankle Orthosis enables the clinician to ... ankle joint to control muscle imbalance ... a pair of bilateral turnbuckles, controlling ... Simply adjust the turnbuckle to gradually ...
... Protection,Protects the heel while maintaining the ankle ... contact with a soft, cushioning AliPlast™ foam ... and liner cradles the heel in a ... change position freely in bed from side-lying ...
... Pediatric Ankle Cryo/Cuff is specifically designed to ... Using a combination of controlled compression and ... pain. The Pediatric Ankle Cryo/Cuff is ideal ... episodes in hemophilia.,The Pediatric Ankle Cryo/Cuff is ...
SCD Sequential Compression System Intermittent Pneumatic Compression...
Medicine Products: